Sacubitril/Valsartan in Patients with HFrEF Undergoing Maintenance Hemodialysis, Evidence of Cardiac Reverse Remodeling During 12-Month Follow-Up: Case Series. (PubMed, Reports (MDPI)) - Sep 25, 2026 - "Blood pressure improved, serum potassium remained stable at 4.95 mmol/L, and no severe hyperkalemia, intradialytic hypotension, post-dialysis hypotension, or heart failure-related hospitalization occurred; In this case series, SV was associated with improved cardiac function, reverse remodeling, pulmonary pressure reduction, and an acceptable safety profile in patients with HFrEF undergoing MHD. These findings suggest a potential therapeutic role for SV in selected dialysis patients and support further investigation."
Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease
|
|
Danilo Baccino; Ledio Shurdi; Sonila Mocka; Stefano Cornara; Stefano Ferraro
|